KR20150108945A - 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 - Google Patents
유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 Download PDFInfo
- Publication number
- KR20150108945A KR20150108945A KR1020157025105A KR20157025105A KR20150108945A KR 20150108945 A KR20150108945 A KR 20150108945A KR 1020157025105 A KR1020157025105 A KR 1020157025105A KR 20157025105 A KR20157025105 A KR 20157025105A KR 20150108945 A KR20150108945 A KR 20150108945A
- Authority
- KR
- South Korea
- Prior art keywords
- leu
- ala
- ser
- arg
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/075—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (21)
- (a) SAdV-39의 헥손 단백질, SEQ ID NO: 11의 아미노산 1 내지 940; SAdV-30의 헥손 단백질, SEQ ID NO: 108의 아미노산 1 내지 938; SAdV-25.2의 헥손 단백질, SEQ ID NO: 140의 아미노산 1 내지 933; SAdV-37의 헥손 단백질, SEQ ID NO: 43의 아미노산 1 내지 942; SAdV-38의 헥손 단백질, SEQ ID NO: 75의 아미노산 1 내지 930; SAdV-26의 헥손 단백질, SEQ ID NO: 172의 아미노산 1 내지 937;
(b) SAdV-39의 펜톤 단백질, SEQ ID NO: 6의 아미노산 1 내지 532; SAdV-30의 펜톤 단백질, SEQ ID NO: 103의 아미노산 1 내지 533; SAdV-25.2의 펜톤 단백질, SEQ ID NO: 135의 아미노산 1 내지 531; SAdV-37의 펜톤 단백질, SEQ ID NO: 38의 아미노산 1 내지 542; SAdV-38의 펜톤 단백질, SEQ ID NO: 70의 아미노산 1 내지 539; SAdV-26의 펜톤 단백질, SEQ ID NO: 167의 아미노산 1 내지 546; 및
(c) SAdV-39의 섬유 단백질, SEQ ID NO: 22의 아미노산 1 내지 489, SAdV-30의 섬유 단백질, SEQ ID NO: 118의 아미노산 1 내지 445; SAdV-25.2의 섬유 단백질, SEQ ID NO: 151의 아미노산 1 내지 443; SAdV-37의 섬유 단백질, SEQ ID NO: 54의 아미노산 1 내지 445; SAdV-38의 섬유 단백질, SEQ ID NO: 85의 아미노산 1 내지 425; SAdV-26의 섬유 단백질, SEQ ID NO: 183의 아미노산 1 내지 425;
로 구성되는 군으로부터 선택되는 캡시드 단백질을 포함하는 캡시드를 가지며,
상기 캡시드는 숙주 세포에서 그것의 전사, 번역 및/또는 발현을 지시하는 발현 조절 서열에 작동가능하게 연결된 유전자를 전달하는 이종성 분자를 단백질막으로 싸는 아데노바이러스. - 제 1 항에 있어서, 복제 및 단백질 막화에 필요한 5' 및 3' 아데노바이러스 시스-구성요소를 추가로 포함하는 것을 특징으로 하는 아데노바이러스.
- 제 1 항에 있어서, 상기 아데노바이러스는 E1 유전자의 모두 또는 일부를 결핍하는 것을 특징으로 하는 아데노바이러스.
- 제 3 항에 있어서, 상기 아데노바이러스는 복제-결함인 것을 특징으로 하는 아데노바이러스.
- 제 5 항에 있어서, 상기 바이러스는 하이브리드 캡시드인 것을 특징으로 하는 아데노바이러스.
- 제 5 항에 있어서, 상기 벡터는 SAdV-39, SAdV-30, SAdV-25.2, SAdV-37, SAdV-38, 및 SAdV-26으로부터 선택되는 하나 이상의 캡시드 단백질을 포함하는 것을 특징으로 하는 아데노바이러스.
- SAdV 헥손 단백질의 단편은 길이에 있어서 약 50개의 아미노산의 N-말단 또는 C-말단 절단을 가지는 SEQ ID NO: 11, 108, 140, 43, 75 또는 172의 SAdV 헥손 단백질 또는
SEQ ID NO: 11, 108, 140, 43, 75 또는 172의 아미노산 잔기 125 내지 443;
SEQ ID NO: 11, 108, 140, 43, 75 또는 172의 아미노산 잔기 138 내지 441;
SEQ ID NO: 11, 108, 140, 43, 75 또는 172의 아미노산 잔기 138 내지 163;
SEQ ID NO: 11, 108, 140, 43, 75 또는 172의 아미노산 잔기 170 내지 176; 및
SEQ ID NO: 11, 108, 140, 43, 75 또는 172의 아미노산 잔기 404 내지 430으로 구성되는 군으로부터 선택되는 유인원 아데노바이러스 헥손 단백질의 단편 및 SAdV에 이종성인 핵산 서열을 함유하는 헥손을 포함하는 캡시드를 가지는 재조합 아데노바이러스. - 제 7 항에 있어서, 캡시드는 SAdV-39, SAdV-30, SAdV-25.2, SAdV-37, SAdV-38 또는 SAdV-26 섬유 단백질을 추가로 포함하는 것을 특징으로 하는 재조합 아데노바이러스.
- 제 7 항에 있어서, 캡시드는 추가로 SAdV-39, SAdV-30, SAdV-25.2, SAdV-37, SAdV-38 또는 SAdV-26 펜톤 단백질을 포함하는 것을 특징으로 하는 재조합 아데노바이러스.
- 제 7 항에 있어서, 상기 아데노바이러스는 복제 및 단백질 막화에 필요한 5' 및 3' 아데노바이러스 시스-구성요소를 포함하는 슈도타입화된 아데노바이러스이고, 상기 시스-구성요소는 아데노바이러스 5' 역위 말단 반복 및 아데노바이러스 3' 역위 말단 반복을 포함하는 것을 특징으로 하는 재조합 아데노바이러스.
- 제 7 항에 있어서, 아데노바이러스는 숙주 세포에서 생성물의 발현을 지시하는 서열에 작동가능하게 연결된 생성물을 암호화하는 핵산 서열을 포함하는 것을 특징으로 하는 재조합 아데노바이러스.
- 제 7 항에 있어서, 재조합 아데노바이러스는 하나 이상의 아데노바이러스 유전자를 포함하는 것을 특징으로 하는 재조합 아데노바이러스.
- 제 7 항에 있어서, 재조합 아데노바이러스는 복제-결함인 것을 특징으로 하는 재조합 아데노바이러스.
- 제 13 항에 있어서, 재조합 아데노바이러스는 아데노바이러스 E1에서 결실된 것을 특징으로 하는 재조합 아데노바이러스.
- 약학적으로 허용가능한 담체 중에 제 1 항 내지 제 14 항 중 어느 한 항의 바이러스를 포함하는 조성물.
- 제 1 항 내지 제 14 항 중 어느 한 항에 따르는 바이러스를 피험자에게 전달하는 단계를 포함하는 아데노바이러스 수용체를 가지는 세포를 표적화하는 방법.
- 유인원 아데노바이러스 39 핵산 SEQ ID NO:1의 1 내지 36553 및 그것의 보체;
유인원 아데노바이러스 25.2 핵산 SEQ ID NO: 130의 1 내지 36629 및 그것의 보체;
유인원 아데노바이러스 26 핵산 SEQ ID NO: 162의 1 내지 36628 및 그것의 보체;
유인원 아데노바이러스 30 핵산 SEQ ID NO: 98의 1 내지 36621 및 그것의 보체;
유인원 아데노바이러스 37 핵산 SEQ ID NO: 33의 1 내지 36634 및 그것의 보체; 및
유인원 아데노바이러스 38 핵산 SEQ ID NO: 65의 1 내지 36494 및 그것의 보체
로 구성되는 군으로부터 선택되는 분리된 유인원 아데노바이러스 핵산. - (a) 5' 역위 말단 반복 (ITR) 서열;
(b) 아데노바이러스 E1a 영역;
(c) 아데노바이러스 E1b 영역, 또는 작은 T, 거대한 T, IX, 및 IVa2영역에 대한 오픈리딩프레임으로 구성되는 군 중에서 선택되는 그것의 단편;
(d) pTP, 폴리머라아제, 및 IVa 영역에 대한 오픈리딩프레임을 포함하는 E2b 영역;
(e) L1 영역, 또는 52/55 kD 단백질, 및 IIIa 단백질에 대한 오픈리딩프레임으로 구성되는 군 중에서 선택되는 그것의 단편;
(f) L2 영역, 또는 펜톤, VII, VI, 및 X 단백질에 대한 오픈리딩프레임으로 구성되는 군으로부터 선택되는 그것의 단편;
(g) L3 영역, 또는 VI, 헥손, 또는 엔도프로테아제에 대한 오픈리딩프레임으로 구성되는 군으로부터 선택되는 그것의 단편;
(h) DNA-결합 단백질(DBP)에 대한 오픈리딩프레임을 포함하는 E2a 단백질;
(i) L4 영역, 또는 100 kD 단백질, 33 kD 상동체, 22kD 상동체 및 VIII에 대한 오픈리딩프레임으로 구성되는 군으로부터 선택되는 그것의 단편;
(j) E3 영역, 또는 12.5K, CR1-알파, gp19K, CR1-베타, CR1-감마, CR1-델타, RID-알파, RID-베타, 및 14.7 K에 대한 오픈리딩프레임으로 구성되는 군으로부터 선택되는 그것의 단편;
(k) L5 영역, 또는 섬유 단백질에 대한 오픈리딩프레임으로부터 선택되는 그것의 단편;
(l) E4 영역, 또는 E4 ORF6/7, E4 ORF6, E4 ORF4, E4 ORF3, E4 ORF2, 및 E4 ORF1에 대한 오픈리딩프레임으로 구성되는 군으로부터 선택되는 그것의 단편; 및
(m) 유인원 아데노바이러스 39, SEQ ID NO:1; SAdV-25.2, SEQ ID NO: 130; 유인원 아데노바이러스 26, SEQ ID NO: 162, 유인원 아데노바이러스 30, SEQ ID NO: 98; 유인원 아데노바이러스 37, SEQ ID NO: 33; 유인원 아데노바이러스 38, SEQ ID NO: 65의 3' ITR
로 구성되는 하나 이상의 군으로부터 선택되는 유인원 아데노바이러스 핵산 서열을 포함하는 벡터. - 제 18 항에 따르는 핵산 서열에 의해 암호화되는 유인원 아데노바이러스 단백질.
- SEQ ID NO:30, 127, 159, 62, 95 및 191의 아미노산 서열로부터 선택되는 E1a;
SEQ ID NO:24, 120, 153, 56, 89, 및 185의 아미노산 서열로부터 선택되는 E1b, 작은 T/19K;
SEQ ID NO: 2, 99, 131, 34, 66, 및 163의 아미노산 서열로부터 선택되는 E1b, 거대 T/55K;
SEQ ID NO:3, 100, 132, 35, 67, 및 164의 아미노산 서열로부터 선택되는 IX;
SEQ ID NO:4, 101, 133, 36, 68, 및 165의 아미노산 서열로부터 선택되는 52/55D;
SEQ ID NO:5, 102, 134, 37, 69 및 166의 아미노산 서열로부터 선택되는 IIa;
SEQ ID NO:6, 103, 135, 38, 70, 및 167의 아미노산 서열로부터 선택되는 펜톤;
SEQ ID NO: 7, 104, 136, 39, 71, 및 168의 아미노산 서열로부터 선택되는 VII;
SEQ ID NO: 8, 105, 137, 40, 72, 및 169의 아미노산 서열로부터 선택되는 V;
SEQ ID NO: 9, 106, 138, 41, 73, 및 170의 아미노산 서열로부터 선택되는 pX;
SEQ ID NO: 10, 107, 139, 42, 74, 및 171의 아미노산 서열로부터 선택되는 VI;
SEQ ID NO: 11, 108, 140, 43, 75, 및 172의 아미노산 서열로부터 선택되는 헥손;
SEQ ID NO:12, 109, 141, 44, 76, 및 173의 아미노산 서열로부터 선택되는 엔도프로테아제;
SEQ ID NO: 13, 110, 142, 45, 77, 및 174의 아미노산 서열로부터 선택되는 100 kD;
SEQ ID NO: 32, 129, 161, 64, 97, 97, 및 193의 아미노산 서열로부터 선택되는 33 kD;
SEQ ID NO: 26, 122, 155, 58, 91, 및 187의 아미노산 서열로부터 선택되는 22 kD;
SEQ ID NO: 14, 111, 143, 46, 78, 및 175의 아미노산 서열로부터 선택되는 VIII;
SEQ ID NO: 15, 123, 144, 47, 79, 및 176의 아미노산 서열로부터 선택되는 E3/12.5 K;
SEQ ID NO:27, 112, 156, 59, 92, 및 188의 아미노산 서열로부터 선택되는 CR1-알파;
SEQ ID NO: 16, 124, 145, 48, 87, 및 177의 아미노산 서열로부터 선택되는 gp19K;
SEQ ID NO: 17, 113, 146, 49, 80, 및 178의 아미노산 서열로부터 선택되는 CR1-베타;
SEQ ID NO:18, 114, 147, 50, 81, 및 179의 아미노산 서열로부터 선택되는 CR1-감마;
SEQ ID NO: 19, 115, 148, 51, 82, 180의 아미노산 서열로부터 선택되는 CR1-델타;
SEQ ID NO:20, 116, 149, 52, 83, 및 181의 아미노산 서열로부터 선택되는 RID-알파;
SEQ ID NO:21, 117, 150, 53, 93, 및 182의 아미노산 서열로부터 선택되는 RID-베타;
SEQ ID NO:28, 125, 158, 60, 84, 및 189의 아미노산 서열로부터 선택되는 E3/14.7K; 및
SEQ ID NO:22, 118, 151, 54, 85 및 183의 아미노산 서열로부터 선택되는 섬유소로 구성되는 군으로부터 선택되는 하나 이상의 유인원 아데노바이러스 단백질을 포함하는 조성물. - 제 20 항에 따르는 조성물을 피험자에 전달하는 단계를 포함하며, 상기 조성물은 헥손, 펜톤 및 섬유소로부터 선택되는 하나 이상의 유인원 아데노바이러스 SAdV-39, -25.2, -26, -30, -37, 및 -38 단백질인 아데노바이러스 수용체를 가지는 세포를 표적화하는 방법.
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US453207P | 2007-11-28 | 2007-11-28 | |
| US449907P | 2007-11-28 | 2007-11-28 | |
| US454107P | 2007-11-28 | 2007-11-28 | |
| US446407P | 2007-11-28 | 2007-11-28 | |
| US446107P | 2007-11-28 | 2007-11-28 | |
| US450707P | 2007-11-28 | 2007-11-28 | |
| US61/004,507 | 2007-11-28 | ||
| US61/004,461 | 2007-11-28 | ||
| US61/004,464 | 2007-11-28 | ||
| US61/004,541 | 2007-11-28 | ||
| US61/004,499 | 2007-11-28 | ||
| US61/004,532 | 2007-11-28 | ||
| PCT/US2008/013066 WO2009073104A2 (en) | 2007-11-28 | 2008-11-24 | Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107014132A Division KR101614364B1 (ko) | 2007-11-28 | 2008-11-24 | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167026650A Division KR101761691B1 (ko) | 2007-11-28 | 2008-11-24 | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150108945A true KR20150108945A (ko) | 2015-09-30 |
| KR101662574B1 KR101662574B1 (ko) | 2016-10-05 |
Family
ID=40380705
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157025105A Expired - Fee Related KR101662574B1 (ko) | 2007-11-28 | 2008-11-24 | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 |
| KR1020167026650A Expired - Fee Related KR101761691B1 (ko) | 2007-11-28 | 2008-11-24 | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 |
| KR1020107014132A Expired - Fee Related KR101614364B1 (ko) | 2007-11-28 | 2008-11-24 | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167026650A Expired - Fee Related KR101761691B1 (ko) | 2007-11-28 | 2008-11-24 | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 |
| KR1020107014132A Expired - Fee Related KR101614364B1 (ko) | 2007-11-28 | 2008-11-24 | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8685387B2 (ko) |
| EP (2) | EP2220241B1 (ko) |
| JP (3) | JP5740158B2 (ko) |
| KR (3) | KR101662574B1 (ko) |
| CN (1) | CN101883858B (ko) |
| AU (1) | AU2008331906B2 (ko) |
| BR (1) | BRPI0819783A2 (ko) |
| CA (2) | CA2964396A1 (ko) |
| CY (1) | CY1118351T1 (ko) |
| DK (1) | DK2220241T3 (ko) |
| ES (1) | ES2607029T3 (ko) |
| HR (1) | HRP20161573T1 (ko) |
| HU (1) | HUE032142T2 (ko) |
| LT (1) | LT2220241T (ko) |
| MX (2) | MX2010005858A (ko) |
| PL (1) | PL2220241T3 (ko) |
| PT (1) | PT2220241T (ko) |
| SG (1) | SG10201604001XA (ko) |
| SI (1) | SI2220241T1 (ko) |
| WO (1) | WO2009073104A2 (ko) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101883858B (zh) | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
| CN102131920B (zh) | 2007-11-28 | 2013-11-06 | 宾夕法尼亚大学托管会 | 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用 |
| AU2008331905B2 (en) | 2007-11-28 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Simian subfamily B adenovirus SAdV-28 and uses thereof |
| JP5661476B2 (ja) | 2008-03-04 | 2015-01-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルスSAdV−36、−42.1、−42.2および−44ならびにそれらの用途 |
| WO2010051367A1 (en) | 2008-10-31 | 2010-05-06 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof |
| WO2010085984A1 (en) * | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| PL2391638T3 (pl) * | 2009-02-02 | 2018-11-30 | Glaxosmithkline Biologicals Sa | Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania |
| CA2762203A1 (en) | 2009-05-29 | 2010-12-02 | Soumitra Roy | Simian adenovirus 41 and uses thereof |
| KR20120139672A (ko) * | 2009-11-09 | 2012-12-27 | 젠벡, 인코포레이티드 | 원숭이 아데노바이러스 벡터의 증식 방법 |
| WO2011057254A2 (en) * | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
| AU2011332025B2 (en) * | 2010-11-23 | 2015-06-25 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof |
| US9254320B2 (en) | 2010-12-17 | 2016-02-09 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| US9267112B2 (en) | 2011-05-10 | 2016-02-23 | The Regents Of The University Of California | Adenovirus isolated from Titi Monkeys |
| US10221218B2 (en) | 2011-05-10 | 2019-03-05 | The Regents Of The University Of California | Adenovirus isolated from titi monkeys |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Hbv聚合酶突變體 |
| WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
| TW201318637A (zh) | 2011-09-29 | 2013-05-16 | Transgene Sa | 免疫療法組成物及用於治療c型肝炎病毒感染之療程(一) |
| SG11201407343XA (en) | 2012-05-18 | 2014-12-30 | Univ Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
| US10036009B2 (en) * | 2012-08-03 | 2018-07-31 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| US10941452B2 (en) | 2014-10-06 | 2021-03-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for isolation of circulating tumor cells (CTC) |
| RU2716991C2 (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| EP4523756A3 (en) | 2015-02-13 | 2025-05-28 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| BR112017026523A2 (pt) * | 2015-06-12 | 2018-08-14 | Glaxosmithkline Biologicals Sa | vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado. |
| EP3384035A4 (en) * | 2015-12-02 | 2019-08-07 | Voyager Therapeutics, Inc. | ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| KR102427379B1 (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| IL315358A (en) | 2016-08-18 | 2024-11-01 | Univ California | CRISPR-CAS genome engineering using a modular AAV delivery system |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)治療組成物および方法 |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | ハンチントン病治療組成物および方法 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| AU2018338728B2 (en) | 2017-09-29 | 2025-01-02 | Centre National De La Recherche Scientifique (Cnrs) | Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| EP3697908A1 (en) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| WO2019086461A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| WO2019086450A1 (en) * | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| CN111372943B (zh) * | 2017-10-31 | 2023-12-05 | 扬森疫苗与预防公司 | 腺病毒及其用途 |
| WO2019086466A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| KR20210019996A (ko) | 2018-05-15 | 2021-02-23 | 보이저 테라퓨틱스, 인크. | 파킨슨병의 치료를 위한 조성물 및 방법 |
| WO2019241486A1 (en) | 2018-06-13 | 2019-12-19 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
| EP3823981A4 (en) | 2018-07-17 | 2022-04-06 | Neuromyon Inc. | TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTS EXPRESSING IGF-1 ISOFORMS |
| CN112770812A (zh) | 2018-07-24 | 2021-05-07 | 沃雅戈治疗公司 | 产生基因治疗制剂的系统和方法 |
| EP3856762A1 (en) | 2018-09-28 | 2021-08-04 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| WO2020072844A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| CN113166781A (zh) | 2018-10-15 | 2021-07-23 | 沃雅戈治疗公司 | 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体 |
| WO2020160508A1 (en) | 2019-01-31 | 2020-08-06 | Oregon Health & Science University | Methods for using transcription-dependent directed evolution of aav capsids |
| CN116322740A (zh) | 2020-07-13 | 2023-06-23 | 特兰斯吉恩股份有限公司 | 免疫抑制的治疗 |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| WO2022218997A1 (en) | 2021-04-12 | 2022-10-20 | Centre National De La Recherche Scientifique (Cnrs) | Novel universal vaccine presenting system |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| US20250276095A1 (en) | 2024-03-04 | 2025-09-04 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy |
| WO2025226841A1 (en) | 2024-04-24 | 2025-10-30 | Kate Therapeutics, Inc. | Gene therapy approach for treating disorders associated with tnnt2 |
| WO2025226842A1 (en) | 2024-04-24 | 2025-10-30 | Kate Therapeutics, Inc. | Expression control by drg-expressed mirnas |
| WO2026011008A1 (en) | 2024-07-02 | 2026-01-08 | Kate Therapeutics, Inc. | Expression control by skeletal muscle-expressed mirnas |
| WO2026011009A1 (en) | 2024-07-02 | 2026-01-08 | Kate Therapeutics, Inc. | Compositions and methods for muscle disorders |
| WO2026030242A1 (en) | 2024-07-29 | 2026-02-05 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy |
| WO2026030244A1 (en) | 2024-07-30 | 2026-02-05 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a |
| WO2026050402A1 (en) | 2024-08-29 | 2026-03-05 | Kate Therapeutics, Inc. | Liver de-targeted muscle tropic capsids |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005071093A2 (en) * | 2004-01-23 | 2005-08-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Chimpanzee adenovirus vaccine carriers |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1364343A1 (ru) | 1984-07-13 | 1988-01-07 | Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов | Способ получени человеческого лейкоцитарного интерферона альфа-2 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4732683A (en) | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| WO1996012406A1 (en) | 1994-10-19 | 1996-05-02 | Genetic Therapy, Inc. | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| DE69534166T2 (de) | 1994-10-28 | 2006-03-09 | Trustees Of The University Of Pennsylvania | Rekombinanter adenovirus und methoden zu dessen verwendung |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US5922315A (en) | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
| US5891994A (en) | 1997-07-11 | 1999-04-06 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| EP1015619A1 (en) | 1997-09-19 | 2000-07-05 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| WO1999014354A1 (en) | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
| AU1822499A (en) * | 1997-12-12 | 1999-06-28 | Saint Louis University | Ctip, a novel protein that interacts with ctbp and uses therefor |
| EP1064393B1 (en) | 1998-03-20 | 2004-12-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| WO2000011140A1 (en) | 1998-08-20 | 2000-03-02 | The Wistar Institute Of Anatomy And Biology | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| BR0107972A (pt) | 2000-01-31 | 2002-11-05 | Smithkline Beecham Biologicals | Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| EP1409748B1 (en) * | 2001-06-22 | 2011-10-26 | The Trustees of The University of Pennsylvania | Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof. |
| AU2002365366B2 (en) * | 2001-11-21 | 2007-05-10 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| CA2528511C (en) * | 2003-06-20 | 2015-11-03 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| WO2006003521A1 (en) | 2004-02-06 | 2006-01-12 | Monash University | High dose, short interval use of sulfated polysaccharides for the treatment of infections |
| EA016648B1 (ru) | 2004-10-14 | 2012-06-29 | Круселл Холланд Б.В. | Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии |
| AU2006212012B2 (en) | 2005-02-12 | 2011-10-13 | Swedish Orphan Biovitrum International Ab | Methods and uses of antibodies in the purification of interferon |
| AR053275A1 (es) * | 2005-05-12 | 2007-04-25 | Glaxo Group Ltd | Composicion de vacuna |
| EP2012822B1 (en) | 2006-04-28 | 2010-01-20 | The Trustees of the University of Pennsylvania | Modified adenovirus hexon protein and uses thereof |
| CN102131920B (zh) | 2007-11-28 | 2013-11-06 | 宾夕法尼亚大学托管会 | 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用 |
| AU2008331905B2 (en) * | 2007-11-28 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Simian subfamily B adenovirus SAdV-28 and uses thereof |
| CN101883858B (zh) | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
| JP5661476B2 (ja) | 2008-03-04 | 2015-01-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルスSAdV−36、−42.1、−42.2および−44ならびにそれらの用途 |
| EP2777185B1 (en) | 2011-10-13 | 2016-08-24 | Telefonaktiebolaget LM Ericsson (publ) | Method and node related to channel estimation |
-
2008
- 2008-11-24 CN CN200880118591.5A patent/CN101883858B/zh not_active Expired - Fee Related
- 2008-11-24 MX MX2010005858A patent/MX2010005858A/es active IP Right Grant
- 2008-11-24 JP JP2010535987A patent/JP5740158B2/ja not_active Expired - Fee Related
- 2008-11-24 SG SG10201604001XA patent/SG10201604001XA/en unknown
- 2008-11-24 ES ES08857159.1T patent/ES2607029T3/es active Active
- 2008-11-24 KR KR1020157025105A patent/KR101662574B1/ko not_active Expired - Fee Related
- 2008-11-24 KR KR1020167026650A patent/KR101761691B1/ko not_active Expired - Fee Related
- 2008-11-24 CA CA2964396A patent/CA2964396A1/en not_active Abandoned
- 2008-11-24 PL PL08857159T patent/PL2220241T3/pl unknown
- 2008-11-24 SI SI200831730T patent/SI2220241T1/sl unknown
- 2008-11-24 BR BRPI0819783-0A patent/BRPI0819783A2/pt not_active IP Right Cessation
- 2008-11-24 AU AU2008331906A patent/AU2008331906B2/en not_active Ceased
- 2008-11-24 LT LTEP08857159.1T patent/LT2220241T/lt unknown
- 2008-11-24 DK DK08857159.1T patent/DK2220241T3/en active
- 2008-11-24 PT PT88571591T patent/PT2220241T/pt unknown
- 2008-11-24 MX MX2014000110A patent/MX347246B/es unknown
- 2008-11-24 EP EP08857159.1A patent/EP2220241B1/en not_active Not-in-force
- 2008-11-24 US US12/744,441 patent/US8685387B2/en active Active
- 2008-11-24 KR KR1020107014132A patent/KR101614364B1/ko not_active Expired - Fee Related
- 2008-11-24 HR HRP20161573TT patent/HRP20161573T1/hr unknown
- 2008-11-24 HU HUE08857159A patent/HUE032142T2/en unknown
- 2008-11-24 CA CA2706258A patent/CA2706258C/en not_active Expired - Fee Related
- 2008-11-24 EP EP16188300.4A patent/EP3128010A1/en not_active Withdrawn
- 2008-11-24 WO PCT/US2008/013066 patent/WO2009073104A2/en not_active Ceased
-
2014
- 2014-02-12 US US14/178,738 patent/US9359618B2/en active Active
- 2014-12-05 JP JP2014246768A patent/JP2015083006A/ja active Pending
-
2016
- 2016-05-13 US US15/154,368 patent/US20160244783A1/en not_active Abandoned
- 2016-05-18 JP JP2016099660A patent/JP6224769B2/ja not_active Expired - Fee Related
- 2016-12-13 CY CY20161101281T patent/CY1118351T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005071093A2 (en) * | 2004-01-23 | 2005-08-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Chimpanzee adenovirus vaccine carriers |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101662574B1 (ko) | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 | |
| KR101761683B1 (ko) | 유인원 아과 b 아데노바이러스 sadv-28,27,-29,-32,-33, 및 -35 및 그것의 사용 | |
| KR101614369B1 (ko) | 유인원 아과 c 아데노바이러스 sadv-40, -31, 및 -34 및 그것의 사용 | |
| AU2011332025B2 (en) | Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof | |
| EP1409748B1 (en) | Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof. | |
| WO2005001103A2 (en) | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses | |
| AU2014203073B2 (en) | Simian E adenovirus SAdV-30 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 St.27 status event code: A-0-1-A10-A18-div-PA0104 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 St.27 status event code: A-0-1-A10-A18-div-PA0104 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
Fee payment year number: 1 St.27 status event code: A-2-2-U10-U12-oth-PR1002 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |
|
| PC1903 | Unpaid annual fee |
Not in force date: 20190929 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE St.27 status event code: A-4-4-U10-U13-oth-PC1903 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20190929 St.27 status event code: N-4-6-H10-H13-oth-PC1903 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |










